exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088234 RNA Name: hsa-miR-3654 RNA Type: miRNA Chromosome: chr7 Starnd: - Coordinate: Start Site(bp): 133034860 End Site(bp): 133034878 External Links: hsa-miR-3654

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand TUBB chr6 30720352 30725426 + DEPDC1B chr5 60596912 60700190 - ERI2 chr16 20780193 20900349 - CCT7 chr2 73233420 73253021 + APLP2 chr11 130068147 130144811 + MRPL11 chr11 66435075 66466738 - HSPA8 chr11 123057489 123063230 - GGH chr8 63015079 63038806 - MDK chr11 46380756 46383837 + EGR1 chr5 138465479 138469303 + MKRN1 chr7 140453033 140479536 - RPS14 chr5 150442635 150449739 - DDTL chr22 23966888 23972556 + DCAF8 chr1 160215715 160262549 - RNPS1 chr16 2253116 2268397 - DCPS chr11 126304060 126350005 + MPRIP chr17 17042545 17217679 + RPL12 chr9 127447674 127451406 - RPL13A chr19 49487554 49492308 + RPS12 chr6 132814569 132817564 + HLA-DRA chr6 32439878 32445046 + STMN1 chr1 25884181 25906991 - RPS3 chr11 75399515 75422280 + RPL3 chr22 39312882 39320389 - FTH1 chr11 61959718 61967634 - TSPAN18 chr11 44726465 44932423 + HLA-DRB5 chr6 32517353 32530287 - NOLC1 chr10 102152176 102163871 + HMGA1 chr6 34236873 34246231 + CCDC85C chr14 99500190 99604207 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AD000090.1 chr19 35557956 35581954 + BCDIN3D-AS1 chr12 49827913 49841143 + LINC00996 chr7 150433654 150448140 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.